cPLA2 CRISPR Activation Plasmid (m): sc-422284-ACT
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- cPLA2 CRISPR Activation Plasmid (m) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- cPLA2 CRISPR Activation Plasmid (m) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by cPLA2 CRISPR Activation Plasmid (m) and cPLA2 CRISPR Activation Plasmid (m2) target distinct regulatory regions upstream of the Pla2g4a transcriptional start site. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: cPLA2 Antibody (4-4B-3C): sc-454
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
cPLA2 CRISPR Activation Plasmid (m) | sc-422284-ACT | 20 µg | $397.00 | |||
cPLA2 CRISPR Activation Plasmid (m2) | sc-422284-ACT-2 | 20 µg | $397.00 |
Pla2g4a encodes cytosolic phospholipase A2 (cPLA2), a Ca2+-dependent, phosphorylation-regulated enzyme that selectively hydrolyzes membrane phospholipids to liberate arachidonic acid and lysophospholipids. This step supplies substrate for cyclooxygenase and lipoxygenase pathways, shaping eicosanoid production and downstream inflammatory and immune signaling. cPLA2 activity is integrated with MAPK/ERK signaling, Ca2+ flux, and membrane trafficking dynamics, influencing cytokine responses, oxidative stress, and barrier function. Dysregulated PLA2G4A/cPLA2 signaling has been linked to inflammatory pathobiology, metabolic stress responses, and neuroinflammatory processes, making it a useful node for mechanistic studies in mouse models.
cPLA2 CRISPR Activation Plasmid (m) provides a targeted, non-destructive approach to upregulating endogenous Pla2g4a expression without altering the underlying DNA sequence.
cPLA2 CRISPR Activation Plasmid (m) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the Pla2g4a locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the Pla2g4a transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous cPLA2 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native Pla2g4a locus and enabling the study of cPLA2-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of cPLA2 pathway restoration in tumor cells with silenced or reduced Pla2g4a expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.